Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology International"
DOI: 10.1007/s12072-021-10280-w
Abstract: Background and aims Liver stiffness measurement (LSM) alone or its combination with platelet counts [Baveno-VI criteria (B6C)] is an important non-invasive tool to predict risk of clinical decompensation in patients with advanced compensated cirrhosis. We… read more here.
Keywords: decompensation; beta blockers; liver stiffness; clinical decompensation ... See more keywords
Frailty as tested by the Liver Frailty Index is associated with decompensation and unplanned hospitalization in patients with compensated cirrhosis
Sign Up to like & getrecommendations! Published in 2021 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2021.1957497
Abstract: Abstract Background and Aims Frailty is associated with morbidity and mortality in advanced cirrhosis. However, the information on the association between frailty and outcome in compensated cirrhosis is scarce. We aimed to explore the prognostic… read more here.
Keywords: compensated cirrhosis; decompensation; frailty; unplanned hospitalization ... See more keywords
Thick Fibrous Septa on Liver Biopsy Specimens Predict the Development of Decompensation in Patients With Compensated Cirrhosis.
Sign Up to like & getrecommendations! Published in 2021 at "American journal of clinical pathology"
DOI: 10.1093/ajcp/aqab024
Abstract: OBJECTIVES In compensated cirrhosis, thick fibrous septa and small nodules on liver biopsy specimens correlate with the presence of clinically significant portal hypertension (CSPH). In turn, CSPH is the strongest predictor of cirrhosis decompensation. The… read more here.
Keywords: compensated cirrhosis; cirrhosis; liver biopsy; patients compensated ... See more keywords
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
Sign Up to like & getrecommendations! Published in 2023 at "Hepatology"
DOI: 10.1097/hep.0000000000000037
Abstract: Background: Comparative outcomes of HBV-infected compensated cirrhosis with low-level viremia (LLV) versus maintained virological response (MVR) are unclear. We conducted a large, multiethnic, multicenter study to examine the natural history of LLV versus MVR in… read more here.
Keywords: compensated cirrhosis; spontaneous mvr; mvr; avt mvr ... See more keywords
Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis
Sign Up to like & getrecommendations! Published in 2023 at "Hepatology"
DOI: 10.1097/hep.0000000000000316
Abstract: Background and Aims: Patients with compensated cirrhosis with clinically significant portal hypertension (CSPH: HVPG >10 mm Hg) have a high risk of decompensation. HVPG is, however, an invasive procedure not available in all centers. The… read more here.
Keywords: risk decompensation; compensated cirrhosis; model; patients compensated ... See more keywords
Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic HCV infection in a real-word setting: a large, multicenter study from Japan.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of gastroenterology and hepatology"
DOI: 10.1111/jgh.14982
Abstract: BACKGROUND The presence of cirrhosis is an important factor for the management of patients with hepatitis C virus (HCV) infection and it determines the duration of treatment for HCV with the direct-acting antiviral (DAA) regimen… read more here.
Keywords: compensated cirrhosis; cirrhosis; study; hcv infection ... See more keywords
Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Chronic Disease"
DOI: 10.1177/20406223221102791
Abstract: Background: Both tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are known to reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to compare the difference in HCC… read more here.
Keywords: compensated cirrhosis; hcc; hcc risk; group ... See more keywords
Signification of Serum Alpha-Fetoprotein Levels in Cases of Compensated Cirrhosis and Hepatitis C Virus without Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medicine and Life"
DOI: 10.25122/jml-2019-0076
Abstract: AFP (alpha-fetoprotein) levels are increased during the development of HCC (hepatocellular carcinoma); nonetheless, it can also be produced by non-tumoral hepatocytes in conditions of high cell turnover. Our study aims to provide additional data regarding… read more here.
Keywords: compensated cirrhosis; hepatitis; cirrhosis; serum ... See more keywords
Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Hepatology"
DOI: 10.4254/wjh.v14.i6.1248
Abstract: BACKGROUND Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and hepatocellular carcinoma globally. Sofosbuvir/velpatasvir (SOF/VEL) is an effective pan-genotypic direct-acting antiviral combination for treatment of chronic HCV infection. While the addition of… read more here.
Keywords: compensated cirrhosis; sof vel; gt3 compensated; cirrhosis patients ... See more keywords